Alopecia areata investigational assessment guidelines–Part II

Olsen, Elise A.; Hordinsky, Maria; Price, Vera H.; Roberts, Janet L.; Shapiro, Jerry; Canfield, Doug; Duvic, Madeleine; King, Lloyd E.; McMichael, Amy J.; Randall, Valerie A.; Turner, Maria L.; Sperling, Leonard C.; Whiting, David; Norris, David A.

doi:10.1016/j.jaad.2003.09.032

Cited by 612 publications

(549 citation statements)

References 15 publications

Supporting

Mentioning

521

Contrasting

Unclassified

Order By: Relevance

“…9 Peripheral blood samples were obtained, with informed consent, from 113 Japanese patients with extensive AA recruited from dermatology clinics in Hokkaido University, Sapporo, Japan. The age range was 5-76 years (mean 32.2) and included 40 male and 73 female subjects.…”

Section: Methodsmentioning

confidence: 99%

Promoter region polymorphism of macrophage migration inhibitory factor is strong risk factor for young onset of extensive alopecia areata

et al. 2005

View full text Add to dashboard Cite

We have demonstrated that serum macrophage migration inhibitory factor (MIF) was significantly elevated in patients with extensive alopecia areata (AA). Recently, functional polymorphisms have been identified in the MIF promoter region. To address the functional and prognostic relevance of the À173G/C and À794[CATT] 5-8 repeat polymorphisms in MIF genes in patients with extensive AA, 113 patients with extensive AA and 194 healthy controls were genotyped. We found that MIFÀ173*C was a risk factor for early onset (o20 years) of extensive AA (odds ratio for GC heterozygotes with À173G/C was 4.88 (95% CI, 2.04-11.8), P ¼ 0.00038; odds ratio for CC homozygotes with À173G/C was 10.42 (95% CI, 2.56-43.5), P ¼ 0.0011). We found no statistically significant differences in the genotype frequencies of the À794[CATT] 5-8 repeat polymorphism and extensive AA. These results suggest that polymorphisms within the MIFÀ173*C allele confer an increased risk of susceptibility to the extensive forms of AA, especially with an early onset of disease. MIF is therefore suggested to be closely implicated in the pathogenesis of the more extensive forms of AA.

show abstract

Section: Methodsmentioning

confidence: 99%

Promoter region polymorphism of macrophage migration inhibitory factor is strong risk factor for young onset of extensive alopecia areata

et al. 2005

View full text Add to dashboard Cite

show abstract

“…Response rates of topical immunotherapy with DPCP widely range from 4% to 85% in literature and this may be due to the difference in number of patients, type, duration and severity of AA as well as time of treatment and methods of evaluation [10,[24][25][26][27][28][29][30].…”

Section: Discussionmentioning

confidence: 99%

Effect of Fexofenadine as an Adjunct to DPCP in Non-Atopic Patients with Alopecia Areata: A Randomized Clinical Trial

Soltanahmadi¹

2012

J Clin Exp Dermatol

View full text Add to dashboard Cite

Introduction: In this study the effect of fexofenadine as an adjunct to diphenylcyclopropenone (DPCP) in nonatopic patients with Alopecia areata (AA) is investigated. Patients and methods:Prospectively 100 patients with AA having hair loss of more than 25% of the scalp are randomly divided into two groups in group A patients received topical DPCP plus oral fexofenafine, in group B patients received only topical DPCP. Results:Regrowth in group A was better than group B but this was not statistically significant. Eczematous reaction and pruritus was significantly lower in group A than in group B.Discussion: Fexofenadine seems to be of no benefit in patients without underlying contributing situation. Therefore, it can be added to conventional regimen in order to enhance the compliance of patients by reducing discomfort of DPCP treatment. Fexofenadine, an H1 receptor antagonist decreases the production of IFN-γ from T lymphocytes [13], as well as the expression of ICAM-1 on epithelial cells, supporting its efficacy for AA [14]. From these findings, antihistamines are expected to be effective for AA treatment. Indeed, the efficacy of antihistamines for AA has been reported [15][16][17][18][19]. Effect of Fexofenadine as anRecently, it has been reported that fexofenadine rapidly suppresses itch due to DPCP immunotherapy for AA, indicating that fexofenadine is an adequate concomitant drug [20]. Also it is found that fexofenadine is effective for AA of atopic background [19,21]. In this study which is a prospective randomized clinical trial we investigate the effect of fexofenadine as an adjunct to DPCP in non-atopic patients with AA. Patients and MethodsWe surveyed prospectively 100 patients with AA having hair loss of more than 25% of the scalp in Razi hospital from January 2009 to January 2011. We excluded patients with pregnancy, lactation, history of atopy, patients who had received systemic corticosteroid or any other medication within 3 months before starting point of evaluation or for AA; also we excluded patients with cardiovascular disease and blood dyscrasia; we randomly divided the patients into two groups (A and B), their age varied between 6 to 47 years. In group A there were 50 patients who received topical diphenylcyclopropenone (DPCP) plus oral fexofenafine, who took fexofenafine (120 mg/day for adults or 60 mg/day for children); in group B there were 50 patients who received only topical DPCP, in group A we lost 6 patients due to headache (1 patient), vitiligo (1 patient) and discontinue to follow up (4 patients), in group B we lost 4 patients, one patient due to severe eczematous reaction and 3 patients due to discontinue follow up (Figure 1).In group A there were 22 (44%) male and 28 (56%) female; in group B there were 26 (52%) male and 24 (48%) female the mean age was 25 ± 9.2 in group A and 24 ± 8.7 in group B. The severity of AA was evaluated using the Severity of Alopecia Tool (SALT) score proposed in the guidelines of the National Alopecia Areata Foundation [22,23]; S 0 : no hair loss; S...

show abstract

“…Saçlı deri dört ana bölgeye (saçlı deri yüzey alanı; verteks %40, sağ yan %18, sol yan %18, arka yüz %24) ayrılarak, bu bölgelerden her birindeki saç kaybının yüzdesi, saç kaybı oranı ile bu bölgenin katsayısı çarpımından bulunmaktadır. Bütün bölgelerdeki saç kaybı yüzdeleri toplanır; böylece toplam saç kaybı % olarak ifade edilir ve S0-S5 arasında derecelendirilir (S0=Saç kaybı yok, S1=%25, S2=%25-49, S3=%50-74, S4a=%75-99, S4b=%96-99, S5=%100) 21 .…”

Section: Alopesi Areataunclassified

Disease severity scoring systems in dermatology

Bilaç¹,

Şahin²,

Öztürkcan³

2016

TURKDERM

View full text Add to dashboard Cite

Scoring systems have been developed to interpret the disease severity objectively by evaluating the parameters of the disease. Body surface area, visual analogue scale, and physician global assessment are the most frequently used scoring systems for evaluating the clinical severity of the dermatological diseases. Apart from these scoring systems, many specific scoring systems for many dermatological diseases, including acne (acne vulgaris, acne scars), alopecia (androgenetic alopecia, tractional alopecia), bullous diseases (autoimmune bullous diseases, toxic epidermal necrolysis), dermatitis (atopic dermatitis, contact dermatitis, dyshidrotic eczema), hidradenitis suppurativa, hirsutismus, connective tissue diseases (dermatomyositis, skin involvement of systemic lupus erythematosus (LE), discoid LE, scleroderma), lichen planoplaris, mastocytosis, melanocytic lesions, melasma, onychomycosis, oral lichen planus, pityriasis rosea, psoriasis (psoriasis vulgaris, psoriatic arthritis, nail psoriasis), sarcoidosis, urticaria, and vitiligo, have also been developed. Disease severity scoring methods are ever more extensively used in the field of dermatology for clinical practice to form an opinion about the prognosis by determining the disease severity; to decide on the most suitable treatment modality for the patient; to evaluate the efficacy of the applied medication; and to compare the efficiency of different treatment methods in clinical studies. Keywords: Disease severity, scoring system, dermatology Skorlama sistemleri, hastalığa ait parametrelerin değerlendirilerek hastanın klinik şiddetini objektif olarak saptama amacıyla geliştirilmiş olan ölçeklerdir. Vücut yüzey alanı, görsel analog skala ve doktor global değerlendirme skoru dermatolojik hastalıkların klinik şiddetinin değerlendirilmesi amacıyla en sık kullanılan genel skorlama sistemleridir. Bu skorlama sistemleri dışında akne (akne vulgaris, akne skarları), alopesi (androgenetik alopesi, traksiyonel alopesi), Behçet hastalığı, büllöz hastalıklar (otoimmün büllöz hastalıklar, toksik epidermal nekroliz, epidermolizis bülloza), dermatit (atopik dermatit, kontakt dermatit, dishidrotik egzama), hidradenitis suppurativa, hirsutismus, konnektif doku hastalıkları (dermatomyozit, sistemik lupus eritematozusun (LE) deri tutulumu, diskoid LE, skleroderma), liken planopilaris, mastositoz, melanositik lezyonlar-melanom, melazma, mikozis fungoides/Sezary sendromu, onikomikoz, oral liken planus, pitiriyazis rozea, psoriasis (psoriasis vulgaris, psoriatik artrit, tırnak psoriasisi), sarkoidoz, ürtiker ve anjiyoödem ve vitiligo gibi çok sayıda dermatolojik hastalık için spesifik skorlama sistemleri de geliştirilmiştir. Hastalık şiddet skorlama yöntemleri, dermatoloji alanında klinik pratikte hastalığın şiddetinin belirlenerek prognoz hakkında fikir sahibi olunabilmesi, hasta için uygun tedavinin belirlenmesi, uygulanan tedavinin etkinliğinin değerlendirilmesi, klinik araştırmalarda ise farklı tedavi yöntemlerinin etkinliklerinin karşılaştırılabilmesi gibi amaçlarla giderek d...

show abstract

Alopecia areata investigational assessment guidelines–Part II

Cited by 612 publications

References 15 publications

Promoter region polymorphism of macrophage migration inhibitory factor is strong risk factor for young onset of extensive alopecia areata

Promoter region polymorphism of macrophage migration inhibitory factor is strong risk factor for young onset of extensive alopecia areata

Effect of Fexofenadine as an Adjunct to DPCP in Non-Atopic Patients with Alopecia Areata: A Randomized Clinical Trial

Disease severity scoring systems in dermatology

Contact Info

Product

Resources

About